Innovent Biologics Inc. Announces Phase 3 Clinical Study of Picankibart for Psoriasis Innovent Biologics, Inc. has announced the initiation of a Phase 3 clinical study to evaluate picankibart, an anti-IL-23p19 antibody, in treating psoriasis patients who have had an inadequate response to anti-IL-17 antibodies. The study recently completed the first participant dosing and is the first of its kind to explore biologics switching in this patient population. The trial will compare the efficacy of picankibart against IL-17 inhibitors. Previous Phase 2 data indicated that picankibart achieved significant skin lesion clearance in 64.6% of patients after 16 weeks. The study aims to provide clinical evidence supporting picankibart's use as an alternative treatment option for challenging cases of psoriasis. Innovent's new drug application for picankibart for moderate-to-severe plaque psoriasis is currently under review by the NMPA.